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A B S T R A C T
Purpose: To describe changes in utilisation of antiepileptic drugs (AED) by people with epilepsy in the
United Kingdom during 1993–2008.
Methods: Cohort study of 63,586 participants with epilepsy and prescribed AEDs from 434 UK family
practices. Prescriptions for different AEDs and AED combinations were evaluated by calendar year,
gender and age group.
Results: Total follow-up was 361,207 person-years, with 282,080 person-years treated with AEDs and
79,126 person-years untreated. AED monotherapy accounted for 72.6% of treated person years of follow-
up. Carbamazepine and valproates were among the most commonly used medications throughout 1993–
2008. Phenytoin accounted for 39.5% of treated person-years in 1993 declining to 18.3% by 2008. Use of
barbiturates declined from 14.3% in 1993 to 6.0% in 2008. In contrast between 1993 and 2008 there were
substantial increases in the use of lamotrigine (2.0% to 17.0%) and to a lesser extent levetiracetam (0% to
8.6%). Newer AEDs were more frequently prescribed to younger participants, especially women aged 15–
44 years, while older adults were more likely to be prescribed longer established AEDs. In 1993, 201
different AED combinations were prescribed, increasing to 500 different combinations in 2008.
Combinations of sodium valproate and carbamazepine were frequent throughout, while sodium
valproate and lamotrigine was frequent in 2008.
Conclusions: Utilisation of newer AEDs in UK primary care has increased between 1993 and 2008 with
increasing use of diverse combinations of AEDs. The data quantify exposure to AEDs relevant to planning
analytical pharmaco-epidemiological studies, as well as providing information to inform prescribing
policies.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The prevalence of epilepsy, and treatment with antiepileptic
drugs (AEDs), is increasing. A large cohort study from UK primary
care showed that the prevalence of persons ever diagnosed with
epilepsy and prescribed antiepileptic drugs on one or more
occasions increased from 0.9% to 1.2% between 1993 and 2007.1
Prescription of antiepileptic drugs remains the mainstay of seizure
prevention in people with epilepsy.2 Side effects to AEDs, including
both dose-related side effects and idiosyncratic adverse drugs
reactions, represent an important limiting factor in epilepsy
treatment. Older AEDs generally have a less favourable safety
proﬁle.2 Several newer AEDs have now been introduced with the* Corresponding author at: Department of Primary Care and Public Health
Sciences, King’s College London, Capital House, 42 Weston St, London SE1 3QD, UK.
Tel.: +44 (0) 207 848 6631.
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1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.04.014aim of increasing efﬁcacy and reducing side effects.3,4 Safety for
use in pregnancy is an important concern in younger women.5
However, these newer drugs are generally more costly because
they are not initially available in generic formulations. Initial drug
selection is often the responsibility of specialists in neurology,
internal medicine, psychiatry, paediatrics or elderly care. Primary
care physicians may lack experience in selecting and adjusting the
dosage of newer drugs, nevertheless the continuation of anti-
epilepsy drugs is largely managed by them.
Drug utilisation studies in epilepsy serve several purposes. Such
studies provide data on the prevalence of exposure to different
AEDs in a population with epilepsy in order to inform pharmaco-
epidemiological and drug safety studies in AEDs. Drug utilisation
studies also provide descriptive information on the process of
diffusion of newer AEDs into clinical practice in primary care in the
UK, as well as quantitative estimates for the decline in prescribing
of older AEDs. This information may be used to inform clinical
prescribing policies. The present paper therefore reports a
descriptive epidemiological study of antiepileptic drug utilisationvier Ltd. All rights reserved.
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utilisation of all AEDs that were available in the United Kingdom
between 1993 and 2007.
2. Methods
This cohort study utilised data from family practices in the UK
contributing to the UK General Practice Research Database (GPRD)
between 1 January 1993 and 15 October 2008. For entry into the
GPRD, family practice data must be up to standard (UTS) for
research as set out by the GPRD group. Participants were included
in the study cohort if they had ever had a recorded diagnosis of
epilepsy and also had received one or more prescriptions for AEDs
after they were registered with a GPRD practice. Date of onset of
epilepsy was deﬁned as the earliest date at which a participant had
a recorded diagnosis of epilepsy or prescription of AEDs.
Participant follow-up started on the date of ﬁrst AED
prescription after the later of: date of onset of epilepsy, date of
registration with a GPRD practice, date at which the practice began
contributing UTS data to GPRD, or 1 January 1993. Participant
follow-up was censored if the participant died or transferred out of
a GPRD practice, or at the last date at which their practice
contributed UTS data to GPRD. Using this deﬁnition, participants
remained on follow-up after ceasing to receive AED prescriptions.
Treatment was ascertained from recorded prescriptions issued
to patients by their family practice. AEDs were identiﬁed from the
unique product codes that are used to code prescriptions into
primary care electronic records. The following categories of
medication were used: barbiturates (phenobarbital, phenobarbital
sodium, methylphenobarbital); valproates (valproic acid, sodium
valproate); phenytoin (phenytoin, phenytoin sodium); fospheny-
toin sodium; carbamazepine; oxcarbazepine; topiramate; primi-
done; ethosuximide; mesuximide; clobazam; clonazepam;
gabapentin; pregabalin; vigabatrin; tiagabine; sultiame; zonisa-
mide; beclamide; lamotrigine; lacosamide; levetiracetam; ruﬁna-
mide; stiripentol. To calculate person-years of exposure to each
AED, participants were considered currently treated with an AED
for the 90 days following each prescription. Previous analyses
show that precise duration of prescription cannot be reconstructed
for a signiﬁcant proportion of GPRD prescriptions. A period of 90
days was established as an average treatment interval from a
previous study of participants with diabetes.
To examine trends in AED utilisation we examined both
number of concurrent AEDs prescribed and type of AED prescribed
for each year between 1993 and 2008. The total number of person-
years of follow-up and AED treated follow-up was calculated forTable 1







1993 220 9121 10,190 
1994 227 11,077 11,737 
1995 233 12,532 12,994 
1996 244 14,005 14,674 
1997 269 16,113 16,725 
1998 290 18,059 18,596 
1999 322 20,442 21,155 
2000 345 22,685 23,635 
2001 366 24,948 25,996 
2002 390 27,130 27,698 
2003 395 28,433 29,157 
2004 397 30,063 30,913 
2005 401 31,663 32,128 
2006 402 32,785 32,807 
2007 394 33,204 33,168 
2008 386 33,131 19,632 
a At start of year IQR = inter-quartile range.each calendar year by age group (0–14, 15–44, 45–64, 65+ years)
and gender. For each year, age group and gender category, we then
calculated: (1) the number of person-years of treatment with each
type of AED; (2) number of person-years of treatment with AED
monotherapy, two concurrent AEDs, three concurrent AEDs, and
four or more concurrent AEDs. The trends in types and number of
AEDs, and AED combinations, prescribed were then presented as a
proportion of AED treated person years for all participants and by
age and gender.
3. Results
The cohort of participants included 63,586 participants from
434 family practices. Total follow-up was 361,207 person-years, of
which 282,080 person-years were treated with AEDs and 79,126
person-years not treated with AEDs. The median duration that
individual participants remained in the study was 4.50 person-
years (inter-quartile range (IQR): 1.74, 8.67). The median number
of person-years that were AED treated was 2.97 (IQR: 0.98, 6.86),
with a median of 0.66 (IQR: 0.14, 2.75) not AED treated. Table 1
gives the characteristics of the participants who were on follow-up
at the start of each calendar year from 1993 to 2008. There are
fewer years of follow-up in 2008 because GPRD data were only
available for part of this year.
Participants were most commonly treated with AED mono-
therapy, which accounted for 72.6% of person-years of treated
follow-up. Participants were treated with two AEDs during 21.9%
of person-years of follow-up, three medications for 4.7% of follow-
up and four or more medications for 0.8% of follow-up. The most
commonly used medications were carbamazepine, valproates and
phenytoin, which were all utilised for greater than 25% of AED
treated follow-up (Table 2). Three medications (mesuximide,
beclamide, lacosamide) were not prescribed to any participants
during follow-up. An additional four medications (sultiame,
ruﬁnamide, fosphenytoin sodium, stiripentol) were used for less
than 5 person-years.
There was little change in the number of concurrent AEDs
prescribed to patients between 1993 and 2008. The types of AED
that were prescribed showed substantial changes from 1993 to
2008 (Figs. 1 and 2). Carbamazepine and valproates were among
the most commonly used medications throughout 1993–2008.
Although phenytoin was the medication with greatest use in 1993
at 39.5% of treated person-years, treatment with phenytoin
declined sharply to 18.3% of treated person-years by 2008. Use
of barbiturates also fell from 14.3% in 1993 to 6.0% in 2008. In
contrast between 1993 and 2008 there were substantial increasesNumber (%) malea Mean agea Median (IQR) years after
diagnosis of epilepsya
4565 (50.0) 46.6 9.0 (3.0, 22.0)
5533 (50.0) 46.3 8.0 (3.3, 21.0)
6231 (49.7) 46.0 8.0 (3.5, 21.0)
6963 (49.7) 45.9 8.0 (3.6, 21.0)
8033 (49.9) 45.9 8.4 (3.8, 21.0)
8980 (49.7) 45.7 8.8 (4.0, 21.0)
10,141 (49.6) 45.7 9.0 (4.0, 21.0)
11,343 (50.0) 45.7 9.6 (4.2, 21.0)
12,546 (50.3) 45.8 10.0 (4.4, 21.0)
13,632 (50.2) 46.0 10.2 (4.5, 21.3)
14,275 (50.2) 46.2 10.5 (4.6, 22.0)
15,156 (50.4) 46.4 10.8 (4.6, 22.0)
15,930 (50.3) 46.6 11.0 (4.8, 22.0)
16,509 (50.4) 46.8 11.4 (5.0, 22.0)
16,711 (50.3) 47.0 11.9 (5.3, 23.0)
16,716 (50.5) 47.2 12.1 (5.6, 23.0)
Fig. 2. Time trend in proportion of person-years treated with other antiepileptic
medications: CNZ, clonazepam; GBT, gabapentin; CBM, clobazam; TPM,
topiramate; VGB, vigabatrin; ETX, ethosuximide; OCZ, oxcarbazepine; PGB,
pregabalin; TGB, tiagabine; ZNS, zonisamide; STM, sultiame; RFM, ruﬁnamide;
FSP, fosphenytoin sodium; STP, stiripentol.
Table 2









Carbamazepine (1965) 100,296 27.77 35.56
Valproates (1973) 93,051 25.76 32.99
Phenytoin (1938) 73,154 20.25 25.93
Lamotrigine (1991) 31,986 8.86 11.34
Barbiturates (1912) 24,893 6.89 8.82
Primidone (1952) 8804 2.44 3.12
Levetiracetam (2000) 8313 2.30 2.95
Clonazepam (1979) 7768 2.15 2.75
Gabapentin (1993) 7625 2.11 2.70
Clobazam (1979) 6835 1.89 2.42
Topiramate (1995) 6401 1.77 2.27
Vigabatrin (1973) 3380 0.94 1.20
a The following AEDs were prescribed for less than 1% of treated follow-up:
ethosuximide (1955), oxcarbazepine (2000), pregabalin (2004), tiagabine (1998),
zonisamide (2005), sultiame, ruﬁnamide (2007), fosphenytoin sodium, stiripentol,
mesuximide, beclamide, lacosamide (2008).
b Source: Epilepsy Action, http://www.epilepsy.org.uk/info/druglist [accessed
20.04.12].
Table 3
Changes in utilisation of selected AEDs by age-group and gender. Figures are
percent of person time in year prescribed named drug.
Age-group
(years)
AED (year of UK licence)a Males Females
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levetiracetam (0% to 8.6%). Among the less commonly prescribed
medications vigabatrin declined in use (2.6% to 0.4%), while use
increased for topiramate (0% to 3.8%) and gabapentin (0.1% to 3.4%)
(Fig. 2).
In general there were similar trends in AED utilisation for each
gender and age group. In each age group, use of lamotrigine and
levetiracetam increased and use of phenytoin or barbiturates
declined. However, there were also substantial differences in AED
utilisation between different age groups and between men and
women. In all age groups, carbamazepine and valproates were
among the most highly utilised medications throughout 1993 and
2008. However, valproates showed a substantial decline in the
later part of the observation period for women aged 15–44, from a
peak use of 40.5% in 1999 to 29.5% in 2008.
In all age groups, use of lamotrigine and levetiracetam
increased between 1993 and 2008 (Table 3). Treatment with
Lamotrigine was more common in younger age groups, but the
pattern of use differed between men and women. In males,
treatment with lamotrigine was highest for those aged 0–14 and
showed the greatest increase between 1993 and 2008 in this age
group. In females, use of lamotrigine showed a particularly large
increase between 1993 and 2008 for women aged 15–44. In 1993Fig. 1. Time trend in proportion of person-years treated with most commonly used
antiepileptic medications. CBZ, cabamazepine; VPA, sodium valproate; PHT,
phenytoin; LTG, lamotrigine; BBT, barbiturates; PMD, primidone; LEV, levetiracetam.just 3.7% of person-years were treated with this AED but by 2008 it
was the most commonly used AED in women of this age at 35.4% of
person-years. Treatment with levetiracetam was most frequent in
males and females aged 15–44 in comparison to other age groups.
Treatment with phenytoin or barbiturates declined in all age groups
throughout 1993–2008, but treatment with these medications
remained much more frequent for those of older age (Table 3).
Table 4 presents data concerning the prescription of combina-
tions of AEDs. In 1993, combinations of two or more AEDs
accounted for 28% of treatment episodes. There were 201 distinct
combinations of AEDs in use. The most frequent combination was
of sodium valproate and carbamazepine with combinations of
phenytoin with either barbiturate, carbamazepine or sodium
valproate also being commonly used. The proportion of treatment
episodes that were accounted for by AED combinations was 28% in
2000 and 34% in 2008. The number of distinct AED combinations in1993 2008 1993 2008
0–14 Lamotrigine (1991) 3.9 19.9 3.5 23.8
Levetiracetam (2000) 0 9.4 0 10.0
Valproate (1973) 52.8 52.3 59.1 47.6
Phenytoin (1938) 5.6 1.3 3.4 0.7
Barbiturate (1912) 2.6 1.7 3.8 1.6
15–55 Lamotrigine (1991) 3.1 17.6 3.7 35.4
Levetiracetam (2000) 0 11.4 0 12.8
Valproate (1973) 35.1 43.8 37.1 29.5
Phenytoin (1938) 35.3 9.2 26.4 5.2
Barbiturate (1912) 7.6 0.7 7.8 1.0
45–64 Lamotrigine (1991) 0.9 11.1 0.8 15.1
Levetiracetam (2000) 0 8.4 0 8.0
Valproate (1973) 19.7 32.2 21.0 29.4
Phenytoin (1938) 52.1 26.9 46.1 20.2
Barbiturate (1912) 21.8 7.7 21.3 8.0
65 Lamotrigine (1991) 0.3 7.6 0.2 8.1
Levetiracetam (2000) 0 3.7 0 3.8
Valproate (1973) 16.4 31.1 17.4 30.0
Phenytoin (1938) 54.3 32.5 53.2 30.7
Barbiturate (1912) 18.3 11.0 22.4 13.0
a Source: Epilepsy Action, http://www.epilepsy.org.uk/info/druglist [accessed
20.04.12].
Table 4
Changing utilisation of AED combinations. Figures are frequencies except where stated.
1993 2000 2008
Number of AED treatment episodes 24,538 44,461 12,961
Number of different combinations
prescribed
201 395 500
Number of episodes with
2 AEDS (% treatment episodes)
6803 (28) 12,413 (28) 4426 (34)
Most frequent combinations and
number of treatment episodes in year
VPA/CBZ 1069 VPA/CBZ 1454 VPA/LMT 260
PHT/BBT 950 PHT/BBT 1297 VPA/CBZ 255
PHT/CBZ 582 VPA/LMT 1192 PHT/BBT 186
VPA/PHT 507 CBZ/LMT 730 LMT/LEV 177
PHT/PRI 345 PHT/CBZ 687 CBZ/LEV 167
CBZ/LMT 266 VPA/PHT 677 VPA/LEV 167
CBZ/BBT 158 PHT/PRI 305 CBZ/LMT 155
VPA/LMT 151 CBZ / TPM 236 VPA/PHT 132
CBZ/VGB 143 CBZ / CBM 203 PHT/CBZ 130
VPA/BBT 129 VPA/CBZ/LMT 191 VPA/TPM 89
Abbreviations: CBZ, cabamazepine; VPA, sodium valproate; PHT, phenytoin; LTG, lamotrigine; BBT, barbiturates; PMD, primidone; LEV, Levetiracetam; CBM, clobazam; TPM,
topiramate.
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use of combinations that included either lamotrigine or levetir-
acetam and declining use of phenytoin containing combinations.
However, the combination of phenytoin and barbiturate persisted
as one of the more frequent AED combinations up to 2008.
4. Discussion
This study had the strengths of a very large population-based
sample drawn from family practices throughout the UK. Previous
studies have conﬁrmed the representativeness of the GPRD
population and the validity of diagnoses recorded in GPRD.8,9
Prescription records within GPRD are considered to be accurate
and complete. The study may not have included prescriptions
issued by specialists either in hospital clinics or in private practice.
However, the majority of long-term prescriptions are issued
through primary care in the UK. We restricted the study to
prescriptions issued to participants who had been diagnosed with
epilepsy. AEDs may also be prescribed for other indications but
these were not considered in the present study. A limitation of the
data source is that the type of epilepsy cannot generally be
determined with conﬁdence from primary care records. The
seizure frequency may also be difﬁcult to ascertain reliably. For
these reasons, it may be difﬁcult to judge the appropriateness of
prescribing at the level of the individual participant. The focus of
the present analysis is therefore at the level of aggregated data for
the population at risk.
Participants in the study were diagnosed with epilepsy and had
received at least one prescription for AED since their registration at
the practice. An appreciable proportion of person-time in the cohort
was not treated with AEDs. This raises questions concerning the
persistence of AED therapy in primary care. It is not clear whether
participants were intentionally weaned off AED therapy, or whether
there is a substantial level of prescription non-adherence in primary
care. We have shown that failure to renew medication prescriptions
is a predictor of mortality in epilepsy.1 This issue requires further
investigation in future research studies and practice.
Nearly three quarters of participant follow-up was accounted
for by prescription of AED monotherapy, with prescription of more
than two AEDs accounting for rather less than a quarter of person-
time and just over a quarter of treatment episodes. There have
been substantial reductions over time in the utilisation of older
AEDs including phenytoin and barbiturates and increased utilisa-
tion of newer drugs including lamotrigine. These changes were
observed earliest in younger participants while utilisation of older
AEDs persisted longer in older adults. Gender differences weregenerally modest. However, there appeared to be a more rapid shift
towards newer AEDs in women aged 15–44 years.
The increased range of AEDs available for prescription was
associated with a substantial increase in the number of different
drug combinations that was prescribed, increasing from 201 in
1993 to 500 in 2008. However, changes in prescribing of AEDs in
combination were consistent with overall trends, showing a
decline in the use phenytoin, primidone and barbiturates and
increasing use of lamotrigine and levetiracetam.
These changes are generally consistent with national recom-
mendations for prescribing in epilepsy that have been current
during this period.2,6 A recent revision of guidance for epilepsy
prescribing in England,7 recommends 2 ﬁrst-line AEDs (carbamaze-
pine, lamotrigine) and 3 other alternative monotherapy AEDs
(levetiracetam, oxcarbazepine, sodium valproate). Eight AEDs are
recommended as adjunctive treatment if monotherapy fails. Failure
of adjunctive treatment should lead to the initiation of further
specialist advice, where other AEDs may be considered. Several of
our observations are substantially inconsistent with these recom-
mendations, including the widespread persistent use of phenytoin,
primidone and phenobarbitone, while oxcarbazepine appears to be
under-utilised. However, lack of adherence to current prescribing
guidelines may sometimes occur when there is satisfactory seizure
control on medication initiated many years ago, even though this
medication is no longer recommended for ﬁrst-line treatment.
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